Related Experiment Video
Updated: Jul 12, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Defining and Measuring Cognitive Decline and Clinical Relevance
Carolin Kurz1, Paul Newhouse2, Kate A Wyman-Chick3
1Department of Psychiatry and Psychotherapy, Technical University of Munich, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany. carolin.kurz@mri.tum.de.
Neurology and Therapy
|July 9, 2026
Summary
This study explores cognitive impairment definitions, balancing biomarkers with clinical function. Pragmatic diagnostic approaches are recommended for routine care and research to improve patient outcomes.
Area of Science:
- Neurology
- Gerontology
- Clinical Psychology
Background:
- Cognitive impairment frameworks increasingly use biomarkers but rely on clinical decline and functional impact for classification.
- Mild cognitive impairment (MCI) signifies an intermediate stage between normal aging and dementia, crucial for early detection and intervention.
Purpose of the Study:
- To examine the balance between biological and clinical definitions of cognitive impairment.
- To discuss implications for diagnosis, care, and research in cognitive disorders.
- To propose practical diagnostic strategies for routine care and research settings.
Main Methods:
- Literature review and conceptual analysis of current cognitive impairment frameworks.
- Examination of diagnostic approaches in routine care versus research settings.
- Discussion of challenges in definition standardization and outcome measure alignment.
Main Results:
- A tiered diagnostic approach combining screening, clinical assessment, and informant data is practical for routine care.
- Integrating cognitive performance with functional measures captures clinically meaningful change better than cognition-only endpoints in research.
- Heterogeneity in definitions and outcomes hinders cross-study comparability and integration of patient-relevant benefits.
Conclusions:
- Clinically useful definitions of cognitive impairment must integrate objective deficits with real-world impact.
- Pragmatic, staged diagnostic pathways are optimal for routine clinical practice.
- Future research should prioritize standardization, feasibility, and alignment with patient-centered outcomes.
Related Concept Videos
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...